Lyell Immunopharma

Lyell Immunopharma, Inc. operates as a holding company, which engages in the development of cell-based immunotherapies for human diseases. The company was founded by Richard D. Klausner, Stan Riddell, and Crystal Mackall in June 2018 and is headquartered in South San Francisco, CA.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

SOUTH SAN FRANCISCO, Calif., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T‑cell reprogramming company advancing a diverse pipeline of cell therapies for patients with solid tumors, today reported financial results and business highlights for the third quarter ended September 30, 2023.

Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2023

Presentations to highlight new nonclinical data on product candidates, new technologies, innovations designed to shorten TIL manufacturing and clinical trials in progress Presentations to highlight new nonclinical data on product candidates, new technologies, innovations designed to shorten TIL manufacturing and clinical trials in progress

Lyell Immunopharma Announces the Acceptance of Six Abstracts for Presentation at 2023 Society for Immunotherapy of Cancer (SITC) Annual Meeting

Proof-of-concept manufacturing to be provided by Cellares for a key Lyell CAR T-cell therapy using Cellares' exclusive Cell Shuttle Collaboration to evaluate potential utilization of the Cell Shuttle for future Lyell CAR T-cell clinical trials and commercialization SOUTH SAN FRANCISCO, Calif. , Sept. 11, 2023 /PRNewswire/ --  Cellares , the first Integrated Development and Manufacturing Organization (IDMO) dedicated to clinical and industrial-scale cell therapy manufacturing, and Lyell Immunopharma (NASDAQ: LYEL), a clinical‑stage T-cell reprogramming company advancing a diverse pipeline of cell therapies for patients with solid tumors, today announced Lyell will evaluate Cellares' automated manufacturing platform, the Cell Shuttle™, through Cellares' Technology Adoption Partnership (TAP) program.

Cellares and Lyell to Evaluate Automated Manufacturing of Lyell's CAR T-Cell Therapy on Cellares' Cell Shuttle Platform

SOUTH SAN FRANCISCO, Calif., Aug. 31, 2023 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T-cell reprogramming company advancing a diverse pipeline of cell therapies for patients with solid tumors, today announced that members of its senior management team will participate in the following upcoming healthcare conferences:

Lyell Immunopharma to Participate in Upcoming Investor Conferences

Lyell is a developer of personalized T-cell therapies for solid tumors, with two programs targeting various types of solid tumors. Their pipeline includes LYL797, a CART cell targeting TNBC and NSCLC, and LYL845, a TIL targeting melanoma, NSCLC, and CRC. Lyell's proprietary technologies have shown improved proliferation, functionality, and antitumor efficacy in preclinical trials. However, the company's valuation has decreased, and there are concerns about the ROR1 targeting space.

Lyell Immunopharma: Once Huge IPO Now Waiting For Clinical Data

SOUTH SAN FRANCISCO, Calif., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T-cell reprogramming company advancing a diverse pipeline of cell therapies for patients with solid tumors, today reported financial results and business highlights for the second quarter ended June 30, 2023.

Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2023

SOUTH SAN FRANCISCO, Calif., July 05, 2023 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T-cell reprogramming company advancing a diverse pipeline of cell therapies for patients with solid tumors, today announced that Matthew Lang, J.D. has joined the executive management team as Chief Business Officer. In this newly created role, Mr. Lang will serve on Lyell's executive committee and will be responsible for Lyell's legal, compliance, human resources, alliance management and early commercialization teams. He will also serve as Lyell's Chief Legal Officer and Corporate Secretary.

Lyell Immunopharma Appoints Matthew Lang as Chief Business Officer

Lyell Immunopharma is a clinical-stage biotech. Its lead cancer therapy, LYL797, in phase 1 trials.

Why Shares of Lyell Immunopharma Jumped This Week

MicroVision

Ammo

It was another wild ride in the stock market today. Whether you were trading penny stocks or Tesla, the thing weighing on everyone's conscience was the outcome of the June Fed meeting.

3 Red Hot Penny Stocks To Watch Before Next Week, Time To Buy?

Lyell Immunopharma (LYEL) came out with a quarterly loss of $0.27 per share versus the Zacks Consensus Estimate of a loss of $0.28. This compares to loss of $0.28 per share a year ago.

Lyell Immunopharma (LYEL) Reports Q1 Loss, Lags Revenue Estimates

SOUTH SAN FRANCISCO, Calif., May 04, 2023 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T-cell reprogramming company advancing a diverse pipeline of cell therapies for patients with solid tumors today reported financial results and business highlights for the first quarter ended March 31, 2023.

Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2023

SOUTH SAN FRANCISCO, Calif., May 02, 2023 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T-cell reprogramming company advancing a diverse pipeline of cell therapies for patients with solid tumors, today announced that members of its senior management team will participate in the BofA Securities 2023 Healthcare Conference on Tuesday, May 9 at 3:00 pm PT.

Lyell Immunopharma to Participate in BofA Securities Healthcare Conference

Lyell Immunopharma (LYEL) delivered earnings and revenue surprises of 90.32% and 1,597.76%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Lyell Immunopharma (LYEL) Reports Q4 Loss, Tops Revenue Estimates

SOUTH SAN FRANCISCO, Calif., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T-cell reprogramming company advancing a diverse pipeline of cell therapies for patients with solid tumors today reported financial results and business highlights for the fourth quarter and year ended December 31, 2022.

Lyell Immunopharma Reports Business Highlights and Financial Results for the Fourth Quarter and Full Year 2022

SOUTH SAN FRANCISCO, Calif., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical-stage T-cell reprogramming company dedicated to developing curative cell therapies for patients with solid tumors, announced today that members of its senior management team will present and participate in the 41st Annual J.P. Morgan Healthcare Conference on Tuesday, January 10 at 4:30 pm Pacific Time.

Lyell Immunopharma to Participate in 41st Annual J.P. Morgan Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Dec. 15, 2022 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T-cell reprogramming company dedicated to developing curative cell therapies for patients with solid tumors, announced that Lynn Seely, MD, a member of the company's board and former president and chief executive officer (CEO) of Myovant Sciences, has been named Lyell's president & CEO effective today. Dr. Seely succeeds Ms. Liz Homans following a four-year tenure as president and then CEO. Ms. Homans will remain a consultant to the company through June 2024.

Lyell Immunopharma Appoints Lynn Seely, MD as President and Chief Executive Officer

Lyell Immunopharma (LYEL) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Lyell Immunopharma (LYEL) Loses 21.6% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

SOUTH SAN FRANCISCO, Calif., Dec. 01, 2022 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T-cell reprogramming company dedicated to developing curative cell therapies for patients with solid tumors, today announced that members of its senior management team will participate in the virtual BofA Securities 2022 Biotech SMID Cap Conference on Thursday, Dec. 8 at 1:40 pm ET.

Lyell Immunopharma to Participate in BofA Securities Biotech Conference

SOUTH SAN FRANCISCO, Calif., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T-cell reprogramming company dedicated to developing curative cell therapies for patients with solid tumors, announced today that members of its senior management team will participate in the Barclays Virtual Fireside Chat Series on Thursday, November 17, at 11 a.m., ET.

Lyell Immunopharma to Participate in Barclays Virtual Fireside Chat Series

Lyell Immunopharma (LYEL) delivered earnings and revenue surprises of 17.65% and 99.96%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Lyell Immunopharma (LYEL) Reports Q3 Loss, Lags Revenue Estimates

SOUTH SAN FRANCISCO, Calif., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Lyell) (Nasdaq: LYEL), a clinical‑stage T-cell reprogramming company dedicated to developing curative cell therapies for patients with solid tumors, today provided business highlights and reported financial results for the third quarter of 2022.

Lyell Immunopharma Reports Recent Business Highlights and Third Quarter Financial Results

SOUTH SAN FRANCISCO, Calif., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical-stage T-cell reprogramming company dedicated to developing curative cell therapies for patients with solid tumors, is presenting preclinical data at the 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) on its product candidates and new genetic and epigenetic reprogramming technologies. This includes new preclinical research on the potential to generate more potent T cells to provide durable anti-tumor functions against certain aggressive solid tumor cancers.

Lyell Immunopharma Presents New Data at SITC Highlighting its Growing Pipeline of T – Cell Reprogramming Technologies and Product Candidates Targeting Solid Tumors

Lyell Immunopharma (LYEL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Lyell Immunopharma (LYEL) Expected to Beat Earnings Estimates: Should You Buy?

SOUTH SAN FRANCISCO, Calif., Oct. 06, 2022 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T-cell reprogramming company dedicated to developing curative cell therapies for patients with solid tumors, announced today that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application to initiate a Phase 1 clinical trial for LYL845. LYL845 is an investigational tumor infiltrating lymphocyte (TIL) therapy enhanced with Lyell's Epi-R™ technology for patients with relapsed and/or refractory metastatic or locally advanced melanoma and other select solid tumors. In preclinical studies, Epi-R creates polyclonal populations of T cells that demonstrate properties of durable stemness and anti-tumor functionality. Durable stemness is the quality that enables T cells to self-renew, proliferate, persist and generate differentiated effector cell progeny.

Lyell Immunopharma Announces FDA Clearance of its IND for LYL845, a TIL Product Candidate Enhanced with its Novel Epigenetic Reprogramming Technology for Solid Tumors

SOUTH SAN FRANCISCO, Calif., Oct. 05, 2022 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical-stage T-cell reprogramming company dedicated to developing curative cell therapies for patients with solid tumors, announced today that five abstracts highlighting preclinical data on its product candidates and new genetic and epigenetic reprogramming technologies were accepted for presentation at the 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) taking place in Boston, Nov. 8 – Nov. 12, 2022. The new preclinical data includes an abstract describing the effects of c-Jun overexpression in combination with NR4A3 gene knockout to enhance the functional activity of ROR1 CAR T cells. The combination of these two genetic reprogramming technologies is being incorporated in Lyell's new product candidate, LYL119, a second generation investigational ROR1 targeting CAR T-cell therapy.

Lyell Immunopharma to Present Preclinical Data Highlighting New T-Cell Reprogramming Technologies and its Growing Pipeline at 2022 Society for Immunotherapy of Cancer (SITC) Annual Meeting

News for Lyell Immunopharma Stock (LYEL)